targeting low her2 expression with antibody-drug conjugates
Published 4 years ago • 102 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
3:34
targeting tumours: challenges of antibody-drug conjugates
-
11:25
podcast 293: her2-“low” breast cancer and its reponse to an antibody-drug conjugate
-
0:46
antibody-drug conjugates in gynecological cancers
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
1:23
antibody-drug conjugates for the treatment of breast cancer
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
6:51
adcs for her2 and her2-low breast cancer
-
1:35
advances in novel adcs for her2-expressing breast cancer
-
30:15
manufacturing concepts for antibody-drug conjugates | webinar
-
11:12
her2-low breast cancer: destiny or good science?
-
43:25
safety considerations for the development of antibody drug conjugates
-
30:50
emerging experts: a discussion with tarantino on her2-low breast cancer and antibody-drug conjugates
-
37:44
clinical perspectives on her2-targeted antibody-drug conjugates: treatment-related adverse events
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
2:21
adcs for the treatment of her2-low breast cancer
-
1:08
targeting her2 in colorectal cancer
-
51:40
trop2-targeting adcs as new tools in the tnbc and hr /her2- breast cancer treatment arsenal
-
1:33:22
transforming metastatic breast cancer management: harnessing the power of antibody-drug conjugate...
-
1:33
antibody-drug conjugates (adcs) in nsclc
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:05:07
the latest in gynecologic cancers: the abcs of adcs (antibody-drug conjugates)
-
35:25
antibody drug conjugates and recent applications in breast cancer treatment